Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

by · The Cerbat Gem

Abbott Laboratories (NYSE:ABT – Get Free Report) had its price target cut by equities researchers at Citigroup from $155.00 to $140.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the healthcare product maker’s stock. Citigroup’s price target indicates a potential upside of 30.63% from the company’s previous close.

ABT has been the subject of a number of other reports. Barclays increased their price objective on Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Evercore ISI lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday. BTIG Research lowered their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler cut their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Daiwa Capital Markets raised their target price on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $140.79.

View Our Latest Analysis on Abbott Laboratories

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock traded down $1.44 on Friday, hitting $107.17. The stock had a trading volume of 13,962,425 shares, compared to its average volume of 9,736,540. The stock has a market cap of $186.36 billion, a price-to-earnings ratio of 13.44, a P/E/G ratio of 2.00 and a beta of 0.72. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 52-week low of $105.78 and a 52-week high of $141.23. The company’s 50 day moving average price is $125.23 and its 200 day moving average price is $128.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. IMG Wealth Management Inc. lifted its holdings in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after acquiring an additional 167 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth $31,000. Finally, Anfield Capital Management LLC boosted its holdings in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

  • Positive Sentiment: Underlying business strength: Med‑tech (devices) and established pharmaceuticals posted solid double‑digit growth, adjusted EPS grew year‑over‑year and management reiterated multi‑year organic sales and EPS growth targets — factors that support the company’s long‑term cash generation and dividend profile. Abbott Reports Fourth‑Quarter and Full‑Year 2025 Results; Issues 2026 Financial Outlook
  • Positive Sentiment: Value/buy thesis emerges after the pullback: commentators and some retail/institutional analysts view the selloff as a buying opportunity given the company’s Dividend King status, scope for share buybacks, and upside to longer‑term targets. Is Abbott’s January Pullback a Good Time to Buy?
  • Neutral Sentiment: Mixed Q4 results: Adjusted EPS matched Street expectations (about $1.50) and revenue rose ~4.4% year‑over‑year, but top‑line fell short of consensus — a mixed beat/miss that leaves fundamentals intact but removes near‑term upside. Abbott Laboratories Q4 2025 earnings call transcript
  • Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics: Nutrition sales contracted (near‑9% decline) as higher retail prices reduced demand and commodity costs remained elevated; diagnostics also weakened as COVID‑related testing continued to normalize — these segmental weaknesses pressured the quarter. ABT Q4 deep dive: Nutrition weakness and innovation shape 2026 outlook
  • Negative Sentiment: Analysts trimmed price targets and adjusted expectations after the revenue miss and guarded guidance — multiple firms cut targets (Sanford Bernstein, Raymond James, Goldman, Piper, etc.), which amplifies downward pressure even when ratings were largely maintained. Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2
  • Negative Sentiment: Bears hedging/increased downside bets: Unusual options activity (large spike in put buying) suggests traders are positioning for further near‑term weakness, which can amplify volatility.
  • Negative Sentiment: Regulatory/integrity risk: Indian authorities are scrutinizing a codeine‑based cough syrup supplied by Abbott’s local unit — a reputational/regulatory overhang that could create incremental uncertainty in certain markets. Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Recommended Stories